Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL

Healthcare
Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Cardiol Therapeutics Inc
Bullboard Posts
User Avatar Image
(2)
•••
Comment by TechnicallyHighon Apr 08, 2019 2:23pm
58 Views
Post# 29597864

RE:Recent report on Pharma Synthetic CBD & Cancer!

RE:Recent report on Pharma Synthetic CBD & Cancer!
MissLeaf wrote: This is a must read article. Found this off Twitter yesterday. Shows the benefits of pharmaceutical grade synthetic CBD over plant-based CBD. Nothing like a pure molecule with no foreign elements in it.

Winner winner chicken dinner folks!  Do your homework!  I believe you will not only see cardiol products on the shelves of shoppers drug Mart, RX Drug stores etc. etc., but you will see this type of synthetic cannabidiol being used in phase 1 and phase 2 trials of some pretty large companies trading in the United States -  most likely gaining faster acceptance for these trials when using a pure molecule.

I still think we will be at $10-$12 here this year, easily!  But don’t believe anything you read on the Internet, do your own homework and get proper guidance on your investments. Cheers!!!

https://ar.iiarjournals.org/content/38/10/5831.full#ref-3


This type of research is probably why the team is optomistic on synthetic CBD treating glioblastama - easily a $10B end market alone. 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities